MIRAPEXFor Patients and Caregivers

Diagnosing RLS

Type sizer AA

RLS is a common yet underdiagnosed condition.10 As a result, several tools have been developed for its diagnosis and evaluation.

Diagnosis

In 1995, a group of experts in the field of RLS formed the International RLS Study Group (IRLSSG) and established 4 essential criteria for RLS diagnosis.12 In 2003, these criteria were updated by the IRLSSG in conjunction with the National Institutes of Health to reflect the existing state of RLS research. These 4 essential criteria are used as the defining characteristics of RLS. When combined with a physical examination and a thorough patient history, an initial diagnosis can be made by adapting diagnostic questions around the essential criteria.11,12

Essential Criteria for RLS Diagnosis11,12

Learn more about clinical evaluation when making a diagnosis of Restless Legs Syndrome (RLS)

Learn more about clinical evaluation when making a diagnosis of Restless Legs Syndrome (RLS)

Learn more about clinical evaluation when making a diagnosis of Restless Legs Syndrome (RLS)

Discover the proven efficacy of MIRAPEX.

Discover the proven efficacy of MIRAPEX. Learn more<.a>

Discover the proven efficacy of MIRAPEX.

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for RLS, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (16% vs. 5%), headache (16% vs. 15%), fatigue (9% vs. 7%) and somnolence (6% vs. 3%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.

Please see full Prescribing Information, including patient information.

If you can't afford your MIRAPEX, our patient assistance program may be able to help. Call 1-800-556-8317

If you can't afford your MIRAPEX, our patient assistance program may be able to help. Call 1-800-556-8317